Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases
Article in Journal of Medicinal Chemistry (February 2024)
The most recent citing publications are shown below. View all 49 publications that cite this research output on Dimensions.
Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4‑(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold
Article in Journal of Medicinal Chemistry (February 2024)
ISABELA Studies: Plasma Exposure and Target Engagement Do Not Explain the Lack of Efficacy of Ziritaxestat in Patients with Idiopathic Pulmonary Fibrosis
Article in Clinical Pharmacology & Therapeutics (January 2024)